Dr. Paolo Paoletti was the first appointed President of GSK Oncology, where he was responsible for championing an organisation of more than 2,000 professionals around the world, dedicated to fighting the causes and impacts of cancer. During his tenure at GSK, seven new medicines were approved globally to treat different types of cancer, generating annual sales of about US$2 billion; these medicines include Arranon/Atriance, Tykerb/Tyverb, Promacta/Revolade, Arzerra, Votrient, Tafinlar and Mekinist.
Prior to joining GSK, Paolo was Vice President of Oncology Clinical Research at Eli Lilly, where he developed ALIMTA platinum chemotherapy. Most recently Paolo was Chief Executive Officer of Kesios Therapeutics Limited.
Paolo has a degree in Medicine from the University of Pisa, where he was Professor in Pulmonary Diseases and authored more than 300 publications. He is currently a non-executive director for PsiOxus Therapeutics, FORMA Therapeutics and Genmab, where he is the Chairman of the Scientific Committee.